Lucentis ranibizumab: Phase III data

Data from the 2-year, U.S. Phase III CATT trial in 1,185 patients with neovascular AMD showed that intravitreal Avastin bevacizumab was non-inferior to Lucentis on the primary endpoint of mean change from baseline in visual acuity at 1 year when the drugs were administered on either a monthly schedule or on an as needed basis. Specifically, patients

Read the full 574 word article

How to gain access

Continue reading with a
two-week free trial.